IDXX vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IDXX and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | IDXX | MRNA |
|---|---|---|
| Company Name | IDEXX Laboratories, Inc. | Moderna, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 50.40 billion USD | 10.86 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | June 21, 1991 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of IDXX and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IDXX | MRNA |
|---|---|---|
| 5-Day Price Return | -0.62% | -1.59% |
| 13-Week Price Return | 16.51% | -14.85% |
| 26-Week Price Return | 53.35% | 8.51% |
| 52-Week Price Return | 33.34% | -52.45% |
| Month-to-Date Return | -1.41% | 8.09% |
| Year-to-Date Return | 52.36% | -32.85% |
| 10-Day Avg. Volume | 0.39M | 10.11M |
| 3-Month Avg. Volume | 0.52M | 10.08M |
| 3-Month Volatility | 61.39% | 51.44% |
| Beta | 1.70 | 1.12 |
Profitability
Return on Equity (TTM)
IDXX
64.42%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
MRNA
-27.46%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
IDXX
24.41%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
A Net Profit Margin of 24.41% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
MRNA
-94.31%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
IDXX
31.09%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
An Operating Profit Margin of 31.09% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MRNA
-106.34%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | IDXX | MRNA |
|---|---|---|
| Return on Equity (TTM) | 64.42% | -27.46% |
| Return on Assets (TTM) | 29.89% | -21.24% |
| Net Profit Margin (TTM) | 24.41% | -94.31% |
| Operating Profit Margin (TTM) | 31.09% | -106.34% |
| Gross Profit Margin (TTM) | 61.54% | 68.32% |
Financial Strength
Current Ratio (MRQ)
IDXX
1.11
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MRNA
3.93
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
IDXX
0.76
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
IDXX’s Debt-to-Equity Ratio of 0.76 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MRNA
0.01
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
IDXX
49.24
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | IDXX | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.11 | 3.93 |
| Quick Ratio (MRQ) | 0.75 | 3.59 |
| Debt-to-Equity Ratio (MRQ) | 0.76 | 0.01 |
| Interest Coverage Ratio (TTM) | 49.24 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IDXX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
IDXX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | IDXX | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
IDXX
51.30
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
A P/E Ratio of 51.30 places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
MRNA
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
IDXX
12.52
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
With a P/S Ratio of 12.52, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
MRNA
3.53
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.53 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
IDXX
29.57
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
MRNA
1.14
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | IDXX | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 51.30 | -- |
| Price-to-Sales Ratio (TTM) | 12.52 | 3.53 |
| Price-to-Book Ratio (MRQ) | 29.57 | 1.14 |
| Price-to-Free Cash Flow Ratio (TTM) | 65.29 | 35.88 |